Welcome to our dedicated page for Painreform SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monitoring how PainReform Ltd (PRFX) funds its PRF-110 extended-release ropivacaine program, navigates the FDA 505(b)(2) pathway, and manages clinical trial costs requires digging through dense biotech disclosures. Those SEC reports often exceed 200 pages, and finding the details that predict dilution risk or milestone timelines can feel impossible.
Stock Titan bridges that gap. Our AI-powered summaries turn every PainReform SEC filing into plain English, so “understanding PainReform SEC documents with AI” is no longer a wish. Our dedicated hub, “PainReform SEC filings explained simply,” ensures you grasp the essentials fast. Whether you need a PainReform quarterly earnings report 10-Q filing to gauge cash burn, or a PainReform 8-K material events explained alert to track trial readouts, we surface the numbers and material language instantly. Real-time PainReform Form 4 insider transactions show when executives buy or sell, while proxy statements reveal compensation aligned to PRF-110 milestones.
Still deciding which document matters? Here’s how investors use the page:
- PainReform annual report 10-K simplified – see R&D spend, liquidity runway, and expected regulatory milestones.
- PainReform earnings report filing analysis – compare quarter-over-quarter expenses and shares outstanding.
- PainReform insider trading Form 4 transactions – monitor management confidence before data releases.
- PainReform proxy statement executive compensation – understand how option grants are tied to FDA approvals.
Each document is tagged, searchable, and updated the moment it hits EDGAR, with PainReform Form 4 insider transactions real-time email alerts. Stop scrolling through legalese; our platform highlights key toxicity data, licensing agreements, and dilution clauses so you can act on facts, not speculation.
Sono-Tek Corporation (NASDAQ: SOTK) filed its Form 10-Q for the fiscal 2026 first quarter ended 31 May 2025. Net sales inched up 2% year-over-year to $5.13 million, driven largely by a repeat high-ASP order in the Alternative/Clean Energy market. A richer product mix and minimal distributor discounts lifted gross margin 310 bps to 51.9%, pushing gross profit up 9% to $2.67 million.
Operating expenses declined 2% to $2.18 million, mainly from lower R&D and selling costs, offset by higher G&A and stock-based compensation. Operating income more than doubled to $0.48 million, and net income rose 47% to $0.48 million ($0.03 per diluted share). Interest and dividend income remained stable at $0.14 million, while a small $0.02 million unrealized securities loss slightly trimmed pre-tax income.
Liquidity & Capital: Cash, cash equivalents and marketable securities totaled $10.9 million (down $1.1 million from year-end) with no debt. Operating cash flow swung to an outflow of $0.92 million, reflecting higher receivables (+$0.75 million), inventory build (+$0.37 million) and income-tax payments. Working capital improved to $13.9 million. The company maintained a $1.5 million unused revolving credit facility (aside from $0.106 million for LC collateral).
Backlog & Concentration: Combined equipment and service backlog declined 14% sequentially to $7.48 million. One customer represented 57% of quarterly sales and 68% of accounts receivable, highlighting concentration risk; management noted revised but collectible payment terms for this account.
Segment & Geographic trends:
- Integrated Coating Systems surged 309% to $3.05 million, now 59% of revenue.
- Multi-Axis Coating Systems fell 75% to $0.68 million on lower clean-energy R&D spending.
- Alt-Energy/Clean market revenue grew 42% to $3.25 million (63% of total).
- U.S./Canada sales jumped 15% to $3.54 million, now 69% of revenue; EMEA dropped 28%.
Capital allocation: Under a $2 million repurchase program, SOTK bought 21,335 shares for $79,479 during the quarter, leaving ~$1.9 million available.
Outlook comments (MD&A) emphasise continued focus on high-value, full-system solutions, expansion of global test labs, and variability in quarterly order flow tied to large machine sales. Management reiterated strong R&D, zero debt and sufficient liquidity to fund growth initiatives.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
What is the primary focus of PainReform Ltd?
How does PainReform differentiate its product offerings?
What regulatory pathway does PainReform utilize for its products?
How does PRF-110 work in managing postoperative pain?
What are the clinical advantages of PainReform's extended-release formulations?
How does PainReform maintain its competitive edge in the specialty pharmaceutical market?
What market segment does PainReform primarily serve?
How does PainReform ensure the quality and efficacy of its products?
